Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 5/20 | 0.55 |
| ▸ | LSS | P48449 | 1/20 | 0.35 |
| ▸ | KIT | P10721 | 5/20 | 0.34 |
| ▸ | CCNA2 | P20248 | 4/20 | 0.34 |
| ▸ | CDK2 | P24941 | 4/20 | 0.34 |
| ▸ | CCNA1 | P78396 | 4/20 | 0.34 |
| ▸ | AURKA | O14965 | 3/20 | 0.34 |
| ▸ | MET | P08581 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | FLT3 | P36888 | 2/20 | 0.33 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.33 |
| ▸ | USP9X | Q93008 | 1/20 | 0.33 |
| ▸ | AXL | P30530 | 1/20 | 0.33 |
| ▸ | INSR | P06213 | 2/20 | 0.32 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.32 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1885711 | 0.89 | IGF1R (0.60) | IGF1RCCNA2CDK2CCNA1AURKA | |
| SCHEMBL1886685 | 0.88 | IGF1R (0.69) | IGF1RLSSKITCCNA2CDK2 | |
| SCHEMBL1890206 | 0.88 | IGF1R (0.56) | IGF1RCCNA2CDK2CCNA1AURKA | |
| SCHEMBL1892263 | 0.88 | IGF1R (0.56) | IGF1RKITCCNA2CDK2CCNA1 | |
| SCHEMBL1888040 | 0.88 | IGF1R (0.51) | IGF1RCCNA2CDK2CCNA1NTRK1 | |
| SCHEMBL1883515 | 0.86 | IGF1R (0.60) | IGF1RCCNA2CDK2CCNA1AURKA | |
| SCHEMBL2677477 | 0.86 | IGF1R (0.54) | IGF1RLSSKITCCNA2CDK2 | |
| SCHEMBL2677466 | 0.86 | IGF1R (0.54) | IGF1RLSSKITAURKAMET | |
| SCHEMBL1887263 | 0.85 | IGF1R (0.58) | IGF1RCCNA2CDK2CCNA1AURKA | |
| SCHEMBL1374088 | 0.85 | IGF1R (0.63) | IGF1RCCNA2CDK2CCNA1NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110230470-A1 | SUBSTITUTED PYRAZOLO[4,3-C]PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-09-22 | — | — | US | disclosed |
| US-7947686-B2 | Substituted pyrazolo[4,3-c]pyridine derivatives active as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230470-A1 | SUBSTITUTED PYRAZOLO[4,3-C]PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS | MAP3K3, MAP3K1, MAP3K19 | IGF1R 760/4885LSS 2649/4885KIT 481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.